KEYNOTE-181: Phase 3, open-label study of second-line pembrolizumab vs single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma

Category Primary study
JournalJournal of Clinical Oncology
Year 2016
This article has no abstract
Epistemonikos ID: 577e696a7fe8a2ef03dba459841634a4860a3bc3
First added on: Feb 07, 2025